Catalyst Event
Hanwha Corp (000880) · Trading Issue
From Akros SCHK HK-Korea Cosmetics Index (ASHKCOS)
7/30/2026, 12:00:00 AM
Hanwha Corp confirmed a corporate spin-off creating Hanwha Machinery & Service Holdings (tentative name), separating the tech and life solutions businesses from the surviving Hanwha Corp, which will retain defense, energy, finance and related core businesses. The action also entails a scheduled trading suspension and distribution of new shares to existing holders.
Korean Translation
2026년 8월 1일 인적분할을 실행할 예정임. 테크 및 라이프 솔루션 사업을 '한화머시너리앤서비스홀딩스(가칭)'로 분리하고, 존속법인은 방산, 에너지, 금융에 집중함. 이번 분할은 복합기업 할인 해소를 목표로 하며 긍정적 반응이 예상됨. 예정됨
Related Recent Events
Hanwha Corp (000880) · Trading Issue
Trading suspension for Hanwha Corp shares is scheduled to begin on 2026-07-30 in connection with the corporate spin-off, with trading expected to resume on 2026-08-25 upon relisting of Hanwha Corp and listing of the spun-off entity.
7/30/2026, 12:00:00 AM
HLB Co Ltd (028300) · Other
The U.S. FDA's final decision on the New Drug Application (NDA) for the Rivoceranib and Camrelizumab combination therapy as a first-line treatment for liver cancer is expected by the PDUFA date of July 23, 2026; this major binary event is expected to have a high price impact expected
7/23/2026, 12:00:00 AM
Samchundang Pharm Co Ltd (000250) · Other
An extraordinary general meeting of shareholders to appoint a new outside director on June 30, 2026, scheduled. Low impact estimated as the appointment of an outside director is a routine administrative matter.
6/30/2026, 12:00:00 AM
Hansoh Pharmaceutical Group Company Limited (3692) · Other
Annual General Meeting on June 26, 2026, to approve 2025 results and dividends. Analysts estimate a 1-5% price impact for this routine corporate event scheduled.
6/26/2026, 12:00:00 AM
Celltrion Inc (068270) · Trading Issue
Bonus issue of 0.05 new shares per common share. The ex-rights date was June 4, 2026, with the new shares scheduled to be listed on June 30, 2026.
6/4/2026, 12:00:00 AM
Innovent Biologics Inc (1801) · Other
Announcement that CLDN18.2 ADC IBI343 (arcotatug tavatecan) met Phase 3 primary endpoint in gastric cancer and NDA was accepted by NMPA; >10% price impact estimated due to first-in-class status expected
6/4/2026, 12:00:00 AM